From Casetext: Smarter Legal Research

Ball v. Takeda Pharm. Am., Inc.

UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT
Dec 15, 2014
587 F. App'x 78 (4th Cir. 2014)

Opinion

No. 13-2338

12-15-2014

MONICA L. BALL, Plaintiff - Appellant, v. TAKEDA PHARMACEUTICALS AMERICA, INCORPORATED; TAKEDA PHARMACEUTICAL COMPANY LIMITED, a Japanese Corporation, Defendants - Appellees, and TAKEDA PHARMACEUTICALS NORTH AMERICA, INCORPORATED; TAKEDA PHARMACEUTICALS INTERNATIONAL, INCORPORATED; TAKEDA PHARMACEUTICALS, LLC; TAKEDA AMERICA HOLDINGS, INC.; TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER, INC.; TAKEDA SAN DIEGO, INC.; TAP PHARMACEUTICALS PRODUCTS, INC., Defendants.

Monica L. Ball, Appellant Pro Se. Damon W.D. Wright, VENABLE, LLP, Washington, D.C., for Appellees.


UNPUBLISHED Appeal from the United States District Court for the Eastern District of Virginia, at Richmond. John A. Gibney, Jr.,
District Judge. (3:13-cv-00168-JAG-MHL)
Before MOTZ, AGEE, and THACKER, Circuit Judges. Affirmed by unpublished per curiam opinion. Monica L. Ball, Appellant Pro Se. Damon W.D. Wright, VENABLE, LLP, Washington, D.C., for Appellees. Unpublished opinions are not binding precedent in this circuit. PER CURIAM:

Monica Ball filed a diversity civil action against Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Limited, and related defendants, alleging product liability and associated Virginia tort claims. On appeal, Ball challenges the district court's orders dismissing her original complaint, in part with leave to amend; dismissing her amended complaint with prejudice; and denying her post-judgment motions. We confine our review to those issues fairly raised in the opening brief. See Town of Nags Head v. Toloczko, 728 F.3d 391, 395 n.4 (4th Cir. 2013) (recognizing that arguments not raised in opening brief are waived). We have reviewed the record and submissions of the parties and find no reversible error or abuse of discretion in the district court's challenged rulings. Accordingly, we affirm for the reasons stated by the district court. See Ball v. Takeda Pharms. Am., Inc., No. 3:13-cv-00168-JAG-MHL (E.D. Va. Apr. 26, 2013; Aug. 8, 2013; Oct. 1, 2013). We deny Ball's motions for appointment of counsel and for an extension of time to file a reply brief. We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before this court and argument would not aid the decisional process.

AFFIRMED


Summaries of

Ball v. Takeda Pharm. Am., Inc.

UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT
Dec 15, 2014
587 F. App'x 78 (4th Cir. 2014)
Case details for

Ball v. Takeda Pharm. Am., Inc.

Case Details

Full title:MONICA L. BALL, Plaintiff - Appellant, v. TAKEDA PHARMACEUTICALS AMERICA…

Court:UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT

Date published: Dec 15, 2014

Citations

587 F. App'x 78 (4th Cir. 2014)

Citing Cases

WILKINS v. Genzyme Corp.

As I have explained, Plaintiffs seem to allege that the Fabrazyme was defective due to contaminants or low…

Vakil v. Bayer Healthcare, LLC

However, "[c]ourts have routinely held warnings adequate as a matter of law when they alert a party to the…